A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin

Acara, Ahmet Çağdaş; Bolatkale, Mustafa; Kızıloğlu, İlker; İbişoğlu, Ersin; Can, Çağdaş

doi:10.1016/j.ajem.2017.12.032

Cited by 49 publications

(41 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asprosin in the circulation could cross the blood-brain barrier and directly activate orexigenic Agouti-related peptide neurons through a cyclic adenosine monophosphate-dependent pathway, leading to appetite stimulation and a drive to accumulate adiposity and bodyweight 17,18 . Acara et al 19 suggested that asprosin might be a novel biochemical marker for predicting the severity of acute coronary syndrome with unstable angina pectoris. Wang et al 20 showed that higher asprosin concentrations before bariatric surgery were associated with the weight reduction magnitude at 6 months after surgery.…”

Section: Discussionmentioning

confidence: 99%

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Zhang

Jiang

et al. 2019

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction Asprosin is a novel secreted adipokine that is induced by fasting and promotes hepatic glucose release. In healthy humans, circulating asprosin shows circadian oscillation with an acute drop coinciding with the onset of eating. The present study investigated whether this circadian oscillation still exists in patients with type 2 diabetes mellitus. Materials and Methods We recruited 60 patients with type 2 diabetes mellitus and 60 individuals with normal glucose tolerance (NGT). All participants completed a 75‐g oral glucose tolerance test. Fasting and 2‐h postprandial serum asprosin concentrations were measured by the enzyme‐linked immunosorbent assay method. Partial correlation coefficients were calculated to analyze the relationships between serum asprosin level and parameters of glucose metabolism. Multiple logistic regression analysis was used to determine the association of serum asprosin level with diabetes. Results Both fasting and postprandial asprosin levels were significantly higher in patients with type 2 diabetes mellitus. The postprandial asprosin level was apparently lower than fasting asprosin level in individuals with NGT. The fasting asprosin level closely correlated with type 2 diabetes mellitus after multiple adjustment (odds ratio 2.329, P = 0.023). Asprosin correlated negatively with change in blood glucose (r = −0.502, P < 0.001) and change in C‐peptide (r = −0.467, P < 0.001) in individuals with NGT, but not in type 2 diabetes mellitus patients. Conclusions Serum asprosin level decreased coinciding with the onset of the oral glucose tolerance test in individuals with NGT, whereas this circadian oscillation was disturbed in type 2 diabetes mellitus patients. The impaired response of asprosin to glucose fluctuation in type 2 diabetes mellitus patients might be one of the reasons for the onset of type 2 diabetes mellitus.

show abstract

Section: Discussionmentioning

confidence: 99%

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Zhang

Jiang

et al. 2019

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…By comparing the levels of asprosin and the scoring system, a study showed that the changes in the levels of asprosin were positively correlated with the Syntax score. This suggested that asprosin could be a viable marker for unstable angina pectoris (UAP), and the severity of acute coronary syndrome (ACS) with UAP might be predicted by it (33).…”

Section: Asprosin In Cvdmentioning

confidence: 99%

Asprosin: A Novel Player in Metabolic Diseases

Yuan

Zhu

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Asprosin, a novel glucogenic adipokine, is encoded by two exons (exon 65 and exon 66) of the gene Fibrillin 1 (FBN1) and mainly synthesized and released by white adipose tissue during fasting. Asprosin plays a complex role in the central nervous system (CNS), peripheral tissues, and organs. It is involved in appetite, glucose metabolism, insulin resistance (IR), cell apoptosis, etc. In this review, we will summarize the newly discovered roles of asprosin in metabolic diseases including diabetes, obesity, polycystic ovarian syndrome (PCOS), and cardiovascular disease (CVD), which may contribute to future clinical diagnosis and treatment.

show abstract

“…On the other hand, in pre-STZ group a significant (p<0.001) decrease in serum levels of glucose, TC, TG, LDL, VLDL, TNF α , % HbA1c and Introduction ASPROSIN, a protein hormone, was discovered by Romere, Duerrschmid [1] and shared in regulation of glucose homeostasis. It is the C-terminal cleavage product of profibrillin and is regulated with the starvation and causes hepatic glucose release by activating hepatic G protein-cAMP-PKA way [2] . Kader, Meltem [3] found that asprosin deficiency in human caused lipodystrophy with reduced plasma insulin.…”

mentioning

confidence: 99%

“…Wang, Qu [4] stated that adipose tissue is considered as an endocrine organ secreting adipokines as asprosin, which participated in the pathologic processes of diabetes mellitus. Asprosin was named after the Greek word for white (aspros), because of the decrease in subcutaneous white adipose tissue that was found in asprosin-deficient patients and because white adipose tissue is a source of plasma asprosin [2] . It was found that plasma asprosin displayed circadian oscillation with an acute drop in levels coinciding with the onset of feeding, while, overnight fasting and insulin resistance increased its circulating levels [1,2] .…”

mentioning

confidence: 99%

“…Asprosin was named after the Greek word for white (aspros), because of the decrease in subcutaneous white adipose tissue that was found in asprosin-deficient patients and because white adipose tissue is a source of plasma asprosin [2] . It was found that plasma asprosin displayed circadian oscillation with an acute drop in levels coinciding with the onset of feeding, while, overnight fasting and insulin resistance increased its circulating levels [1,2] . Also, Wang, Qu [4] found that plasma asprosin levels were significantly higher in patients with type 2 diabetes mellitus in comparison to control persons.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effect of Oxytocin Treatment on Asprosin Serum Level and Liver Function Changes in Rats with Streptozotocin-Induced Diabetes

Abulfadle

Atia²

2018

The Medical Journal of Cairo University

View full text Add to dashboard Cite

Background: Asprosin is a newly discovered hormone that was found to be increased in cases of type 2 diabetes mellitus but, few data were available on its serum level changes in cases of streptozotocin (STZ) induced diabetes. Also, studies on the effect of STZ induced diabetes on liver functions were limited. In addition, exogenous oxytocin treatment was recorded to improve glucose homeostasis in cases of type 2 diabetes mellitus and insulin resistance, but, the information about its effect on STZ induced diabetes was few. Aim of Study:To investigate the effect of exogenous oxytocin treatment on asprosin serum level and liver function changes in rats with STZ-induced diabetes.Material and Methods: 24 Rats were divided equally into 4 groups; control group, streptozotocin treated (STZ) group, streptozotocin treated and pretreated with oxytocin (pre-STZ) group, and, streptozotocin treated and post-treated with oxytocin (post-STZ) group. In the control group, 1ml of saline solution was daily injected intraperitoneally (i.p.) for the 1st 6 days and the last 5 days of this 39 days study. In STZ group, a single dose of STZ (60mg/kg, freshly dissolved in 1 ml of saline solution) was injected i.p. on the 6th day after initial 1 ml of saline solution was daily injected i.p. for the 1 st 5 days. Also, 1ml saline/day was injected i.p. in the last 5 days of the study. In Pre-STZ group, 5 µ g/kg of oxytocin was daily injected i.p. for 5 days prior to the administration of a single dose of STZ injection and in the last 5 days of the study, 1ml of saline was injected i.p. daily. In post-STZ group, 5 µ g/kg of oxytocin was daily injected i.p. for 5 days beginning by 28th day following the administration of single dose of STZ injection on the 5 th day which was preceded by 5 days i.p. therapy with 1ml of saline/day. At the end of the study, rats were fasted overnight and were killed by decapitation while anaesthetized with ether. Blood from each rat was collected and divided into two parts, a part was kept in heparinized tubes for estimation of glycosylated hemoglobin (HbA 1 c) and the other part was left in non-heparinized tubes to clot and was centrifuged to separate serum which was stored at -25ºC till used for chemical assays.Results: In STZ group, there was a significant (p<0.001) increase in serum levels of glucose, total cholesterol (TC), 4417 4418 Effect of Oxytocin Treatment on Asprosin Serum Level & Liver Function Changes atherogenic index, but, there was a significant increase in final BMI (p<0.01) and serum levels (p<0.001) of each of insulin, asprosin, C-peptide and HDL, in comparison to the STZ group was found. Also, significant ( p<0.001) decreases in serum levels of AST, ALT, ALP and total bilirubin, but, significant (p<0.001) increases in serum direct bilirubin, total protein and albumin levels in comparison to the STZ group were found. In post-STZ group, there was a significant (p<0.001) decrease in serum levels of glucose, TC, TG, LDL, VLDL, TNFα , % HbA1c and atherogenic index, but, a significant increase (p<0....

show abstract

A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin

Cited by 49 publications

References 6 publications

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Asprosin: A Novel Player in Metabolic Diseases

Effect of Oxytocin Treatment on Asprosin Serum Level and Liver Function Changes in Rats with Streptozotocin-Induced Diabetes

Contact Info

Product

Resources

About